Metabolic side effects of atypical antipsychotics in children: A literature review

Journal of Psychopharmacology

Volumn 19, Issue 5, 2005, Pages 533-550

  Fedorowicz, Valérie J ^a   Fombonne, Eric ^a,b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adolescents; Atypical antipsychotics; Children; Diabetes; Glycaemia; Lipids; Metabolic; Prolactin; Side effect; Weight

Indexed keywords

AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; CABERGOLINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADJUSTMENT DISORDER; AGGRESSIVENESS; ANXIETY DISORDER; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL; CONDUCT DISORDER; DEPRESSION; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSTHYMIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; MANIA; MEDLINE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROSIS; OBESITY; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD BEHAVIOR DISORDERS; HUMANS; METABOLIC DISEASES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 25844472161     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105056543     Document Type: Review

References (112)

1. Ahren B, Larsson H, Wilhelmsson C, Nasman B, Olsson T (1997) Regulation of circulating leptons in humans. Endocine 7: 1-8
2. Alfaro C L, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport J L (2002) Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12(2): 83-91
3. Allison D B, Fontaine K R, Heo M, Heo M, Mentore J L, Cappelleri J C, Chandler L P, Weiden P J, Cheskin L J (1999) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60: 215-220
4. Aman M G, De Smedt G, Derivan A, Lyons B, Findling R L, Risperidone Disruptive Behaviour Study Group (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159(8): 1337-1346
5. American Association for Child and Adolescent Psychiatry (AACAP) (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 40(7) (Suppl): 4S-23S
6. American Diabetes Association/American Psychiatric Association (ADA/APA) (2004) Consensus Development Conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65(2): 267-72
7. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S (2002) Atypical antipsychotic drug use and diabetes. Psychother Psychosom 71(5): 244-254
8. Ardizzone T D, Bradley R J, Freeman AM 3rd, Dwyer D S (2001) Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 923(1-2): 82-90
9. Basile V S, Masellis M, McIntyre R S, Meltzer H Y, Lieberman J A, Kennedy J L (2001) Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 62(23) (Suppl): 45-66
10. Basson B R, Kino B J, Taylor C C, Szymanski K A, Gilmore J A, Tollefson J D (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62(4): 231-238
11. Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G (2003) Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol 13(1): 97-102
12. Boston P F, Dursun S M, Reveley M A (1996) Cholesterol and mental disorder. Br J Psychiatry 169: 682-689
13. Breum L, Bjerre U, Bak J F, Jacobsen S, Astrup A (1995) Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 40: 1570-1576
14. Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29: 697-701
15. Bryden K E, Carrey N J, Kutcher S P (2001) Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 11(2): 113-130
16. Buitelaar J K (2000) Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10(1): 19-26
17. Buse J B (2002) Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. J Clin Psychiatry 63(4) (Suppl): 37-41
18. Bymaster F P, Calligaro D O, Falcone J F, Marsh R D, Moore N A, Tye N C, Seeman P, Wong D T (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96
19. Carnahan R M, Lund B C, Perry P J (2001) Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 21(6): 717-730
20. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg T M, DeMaso D R (2002) A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 12(4): 337-345
21. Clinton Smith J. (2004) The current epidemic of childhood obesity and its implications for future coronary heart disease. Pediatr Clin North Am 51(6): 1679-1695
22. Cohen L G, Biederman J (2001) Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 11(4): 435-440
23. Deckelbaum R J, Williams C L (2001) Childhood obesity: the health issue. Obes Res 9(4) (Suppl): S239-S243
24. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bull 26(4): 903-912.
25. Eder U, Manweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker W W (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158(10): 1719-1722
26. Findling R L, McNamara N K (2004) Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65(6) (Suppl): 30-44
27. Findling R L, McNamara N K, Gracious B L (2000) Paediatric uses of atypical antipsychotics. Expert Opin Phamacother 1: 935-945
28. Findling R L, McNamara N K, Youngstrom E A, Branicky L A, Demeter C A, Schulz S C (2003) A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 42(2): 170-175
29. Frazier J A, Biederman J, Tohen M, Feldman P D, Jacobs T J, Toma V, Rater M A, Tarazi R A, Kim G S, Garfield S B, Sohma M, Gonzalez-Heydrich J, Risser R C, Nowlin Z M (2001) A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11(3): 239-250
30. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T (1998) A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 153: 208-213
31. Goodwin R, Gould M S, Blanco C, Olfson M (2001) Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv 52(8): 1081-1087
32. Gracious B L, Krysiak T E, Youngstrom E A (2002) Amantadine treatment of psychotropic-induced weight gain in children and adolescents: Case series. J Child Adolesc Psychopharmacol 12(3): 249-257
33. Hack S, Chow B (2001) Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 11: 59-67
34. Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T (2001) Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 62(11): 843-848
35. Harris M I, Flegal K M, Cowie C C, Eberhardt M S, Goldstein D E, Little R R, Wiedmeyer H M, Byrd-Holt D D (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21: 518-524
36. Haupt D W, Newcomer J W (2001) Hyperglycemia and antipsychotic medications. J Clin Psychiatry 62(27) (Suppl): 15-26
37. Hellings J A, Zarcone J R, Crandall K, Wallace D, Schroeder S R (2001) Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11(3): 229-238
38. Henderson D C (2002) Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs 16(2): 77-89
39. Herran A, Garcia-Unzueta M T, Amado J A, de la Maza M T, Alvarez C, Vazquez-Barquero J L (2001) Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 179: 59-62
40. Hong C J, Lin C H, Yu Y W, Yang K H, Tsai S J (2001) Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 11(3): 265-268
41. Howes O D, Bhatnagar A, Gaughran F P, Amiel S A, Murray R M, Pilowsky L S (2004) A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 161(2): 361-363
42. Jin H, Meyer J M, Jeste V J (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14(1): 59-64
43. Jubert R, Fernandez R, Ruiz A (1995) Clozapine-related pancreatitis (letter). Intern Med 122: 397
44. Kato M M, Goodnick P J (2001) Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2(10): 1571-1582
45. Keck P E Jr, McElroy S L, Arnold L M (2001) Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother 2(6): 1033-1042
46. Kelly D L, Conley R R, Love R C, Horn D S, Ushchak C M (1998) Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8(3): 151-159
47. Koller E A, Doraiswamy P M (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22(7): 841-852
48. Koller E A, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111(9): 716-723
49. Krishnamoorthy J, King B H (1998) Open-label olanzapine treatment in 5 preadolescent children. J Child Adolesc Psychopharmacol 8(2): 107-113
50. Kumra S, Frazier J A, Jacobsen L K, McKenna K, Gordon C T, Lenane M C, Hamburger S D, Smith A K, Albus K E, Alaghband-Rad J, Rapoport J L (1996) Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53(12): 1090-1097
51. Lebovitz H E (2003) Metabolic consequences of atypical antipsychotic drugs. Psychiatric Quarterly 74(3): 277-290
52. Lewis R (1998) Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 43: 596-604
53. Lund B C, Perry P J, Brooks J M, Arndt S (2001) Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claim-based approach. Arch Gen Psychiatry 55(12): 1172-1176
54. Malone M L, Gennis V, Goodwin J S (1992) Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc 40: 1100-1104
55. Malone R P, Sheikh R, Zito J M (1999) Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 50(2): 171-174
56. Martin A, L'Ecuyer S (2002) Triglyceride, cholesterol, and weight changes among riperidone-treated youths: A retrospective study. Eur Child Adolesc Psychiatry 11(3): 129-133
57. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman J F (2000) Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10(4): 259-268
58. Martin A (1992) Acute pancreatitis associated with clozapine use (letter). Am J Psychiatry 149: 714
59. Masand P S, Gupta S (2000) Long-term adverse effects of atypical antipsychotics. Psychiatr Prac 6: 299-309
60. Masi G, Cosenza A, Mucci M, Brovedani P (2003) A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64(9): 1039-1047
61. Masi G, Cosenza A, Mucci M (2001) Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11(4): 389-394
62. Masi G, Mucci M, Millepiedi S (2002) Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 12(2): 93-99
63. McConville B J, Arvanitis L A, Thyrum P T, Yeh C, Wilkinson L A, Chaney R O, Foster K D, Sorter M T, Friedman L M, Brown K L, Heubi J E (2000) Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61(4): 252-260
64. McConville B J, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Brown K (2003) Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 13(1): 75-82
65. McConville B J, Sorter M T (2004) Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65(6) (Suppl): 20-29
66. McCracken J T, McGough J, Shah B, Cronin P, Hong D, Aman M G, Arnold L E, Lindsay R, Nash P, Hollway J, McDougle C J, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez N M, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5): 314-321
67. McDougle C J, Kem D L, Posey D J (2002) Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41(8): 921-927
68. McIntyre R S, McCann S M, Kennedy S H (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46(3): 273-281
69. Meatherall R, Younes J (2002) Fatality from olanzapine induced hyperglycemia. J Forensic Sci 47(4): 893-896
70. Melkersson K I, Hulting A L, Brismar K E (1999) Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 60(11): 783-791
71. Melkersson K I, Hulting A L, Brismar K E (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742-749
72. Melkersson K I, Hulting A L (2001) Insulin and leptin levels in patients with schizophrenia or related psychoses-a comparison between different antipsychotic agents. Psychopharmacology 154(2): 205-212
73. Meltzer S, Leiter L, Daneman D, Gerstein H C, Lau D, Ludwig S, Yale J F, Zinman B, Lillie D (1998) 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 159(8) (Suppl): S1-S27
74. Mokdad A H, Bowman B A, Ford E S, Vinicor F, Marks J S, Koplan J P (2001) The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 286: 1195-1200
75. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R (2003) Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13(3): 311-317
76. Mukkades N M, Abali O (2003) Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 13(3): 295-299
77. Nasrallah H (2003) A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28(1) (Suppl): 83-96
78. Newcomer J W (2001) Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry 62(27) (Suppl): 3-4
79. Patel N C, Sanchez R J, Johnsrud M T, Crismon M L (2002) Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 12(3): 221-229
80. Potenza M N, Holmes J P, Kanes S J, McDougle C J (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19(1): 37-44
81. Ramankutty G (2002) Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand 105(3): 235-236
82. Ratner R E (1998) Type 2 diabetes mellitus: the grand overview. Diabet Med 15(4) (Suppl): S4-S7
83. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41(3): 337-343
84. Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 57(11) (Suppl): 4-11
85. Ross R G, Novins D, Farley, G K, Adler L E (2003) A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13(3): 301-309
86. Saito E, Kafantaris V (2002) Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol 12(3): 231-236
87. Sallee F R, Kurlan R, Goetz C J, Singer H, Scahill L, Law G, Dittman V M, Chappell P B (2000) Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39(3): 292-299
88. Schulz E, Fleischhaker C, Remschmidt H E (1996) Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol 6(2): 119-131
89. Sernyak M J, Leslie D L, Alarcon R D, Losonczy M F, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159(4): 561-566
90. Shaw J A, Lewis J E, Pascal S, Sharma R K, Rodriguez R A, Guillen R, Pupo-Guillen M (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11(4): 415-424
91. Sikich L, Hamer R M, Bashford R A, Sheitman B B, Lieberman J A (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacol 29(1): 133-145
92. Simeon J, Milin R, Walker S (2002) A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Nero-Psychopharmacol Biol Psychiatry 26(2): 267-275
93. Sowell M O, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H O, Breier A, Beasley C M Jr, Dananberg J (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87(6): 2918-2923
94. Stigler K A, Potenza M N, Posey, D J, McDougle C J (2004) Weight gain associated with atypical antipsychotic use in children and adolescents. Prevalence, clinical relevance, and management. Pediatr Drugs 6(1): 33-44
95. Tandon R (2002) Safety and tolerability: How do newer generation 'atypical' antipsychotics compare? Psychiatric Q 73(4): 297-311
96. Tecott L H, Sun L M, Akana S F, Strack A M, Lowenstein D H, Dallman M F, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT-sub(2C) serotonin receptors. Nature 374: 542-546
97. Theisen F M, Linden A, Geller F, Schafer H, Martin M, Remschmidt H, Hebebrand J (2001) Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatric Res 35(6): 339-345
98. Torrey E F, Swalwell C I (2003) Fatal olanzapine-induced ketoacidosis. Am J Psychiatry 160(12): 2241
99. Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQ. Pediatrics 110(3): E34
100. Van Bellinghen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11(1): 5-13
101. Wehring H J, Kelly D L, Love R C, Conley R R (2003) Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry 160(12): 2241-2242
102. Wetterling T, Mussigbrodt H E (1999) Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 19(4): 316-321
103. Wilson D R, D'Souza L, Sarkar N, Newton M, Hammond C (2002) New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 59(1): 1-6
104. Wirshing D A (2001) Adverse effects of atypical antipsychotics. J Clin Psychiatry 62(21) (Suppl): 7-10
105. Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C (1998) Novel antipsychotics and new onset diabetes. Biol Psychiatry 44: 778-783
106. Wirshing D A, Wirshing W C, Kysar L, Berisford M A, Goldstein D, Pashdag J, Mintz J, Marder S R (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60: 358-363
107. Woods S W, Martin A, Spector S G, McGlashan T H (2002) Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 41(12): 1439-1446
108. Wudarsky M, Nicolson R, Hamburger S D, Spechler L, Gochman P, Bedwell J, Lenane M C, Rapoport J L (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9(4): 239-245
109. Zalsman G, Cannon E, Martin A, Bensason D, Weizman A, Tyano S (2003) Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13(3): 319-327
110. Zhang Z J, Yao Z J, Liu W, Fang Q, Reynolds G P (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 184: 58-62
111. Zito J M, Safer D J, dosReis S, Gardner J F, Magder L, Soeken K, Boles M, Lynch F, Riddle M A (2003) Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 157: 17-25
112. Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000) Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10(2): 79-90